Monitor the company's final Q1 2026 earnings release for confirmation of this IPR&D charge and any additional details on the underlying transactions. The charge is non-recurring but could signal new strategic partnerships or acquisitions.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 8 $775.36entry
- T+1 · 7mo ago −1.34%α −1.91% · $764.98
- T+5 · 7mo ago −3.06%α −6.58% · $751.63
- T+20 · 7mo ago −9.43%α −17.97% · $702.27
- T+60 · 4mo ago −15.62%α −25.79% · $654.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron Pharmaceuticals expects a $102 million acquired in-process R&D charge in Q1 2026, which will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81. This is a preliminary estimate ahead of final financial statement closing.
Key Facts
- Regeneron expects a $102 million acquired in-process research and development (IPR&D) charge in Q1 2026
- The charge primarily relates to premiums on equity securities purchased, development milestones, and up-front payments from collaboration and licensing agreements
- The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81
- The company notes that actual results may differ from these preliminary estimates as financial statements are not yet finalized
Financial Impact
Approximately $102 million pre-tax charge, reducing EPS by $0.81
Risk Factors
- Actual results may differ from these preliminary estimates
- The IPR&D charge reflects non-cash expenses that could impact investor perception of profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-040661 |
| Document: 0001104659-26-040661-index-headers.html | 0001104659-26-040661 |
| Document: 0001104659-26-040661-index.html | 0001104659-26-040661 |
| Document: 0001104659-26-040661.txt | 0001104659-26-040661 |
| 8-K Data (Synthetic) | 0001104659-26-040661 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers